| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Revenue | $821.5M | +32.2% |
| Cost of Revenue | $211.1M | +17.8% |
| Gross Profit | $610.4M | +38.1% |
| R&D Expense | $267.0M | +22.4% |
| SG&A Expense | $185.5M | -6.4% |
| Operating Income | -$329.4M | +13.0% |
| Pre-tax Income | -$281.6M | +15.4% |
| Income Tax | $6.8M | +16.6% |
| Net Income | -$288.4M |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $186.6M | -27.3% |
| Short-term Investments | $535.3M | -20.0% |
| Accounts Receivable | $236.0M | +10.1% |
| Current Assets | $1.07B | -17.5% |
| Total Assets | $2.41B | +3.7% |
| Current Liabilities | $613.6M | +4.0% |
| Total Liabilities | $737.4M | +1.4% |
| Line Item | 2025-01-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $33.7M | +149.3% |
| Capital Expenditures | $1.9M | +42.6% |
| Investing Cash Flow | -$218.4M | -255.3% |
| Financing Cash Flow | $55.9M | +17.7% |
| Free Cash Flow | $31.9M | +145.7% |
| +14.8% |
| EPS (Basic) | -$0.92 | +20.0% |
| EPS (Diluted) | -$0.92 | +20.0% |
| Stockholders' Equity |
| $1.67B |
| +4.7% |